Aurora Cannabis (ACB) Non-Current Assets (2018 - 2026)
Aurora Cannabis (ACB) posted quarterly Non-Current Assets of $148.5 million for Q1 2026, down 43.08% year-on-year from $260.9 million in Q1 2025, and down 43.08% on a QoQ basis from $260.9 million in Q1 2025.
Aurora Cannabis (ACB) Non-Current Assets (2018 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Non-Current Assets for 9 consecutive years, with $148.5 million the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Assets fell 43.08% year-over-year to $148.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $963.8 million (down 12.97% YoY) and the FY2026 annual result came in at $147.4 million, down 45.28% from the prior year.
- Non-Current Assets declined to $148.5 million in Q1 2026 per ACB's latest filing, from $260.9 million in the prior quarter.
- Over the last five years, Non-Current Assets for ACB reached as high as $330.2 million in Q1 2023 and fell as low as $148.5 million in Q1 2026.
- A 5-year average of $269.7 million and a median of $277.2 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 83.13% — and 2024, when it declined 7.39%.
- Year by year, Non-Current Assets stood at $266.1 million in 2022, then advanced by 24.1% to $330.2 million in 2023, then dropped by 18.97% to $267.5 million in 2024, then declined by 2.49% to $260.9 million in 2025, then sank by 43.08% to $148.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $148.5 million, $260.9 million, and $267.5 million for Q1 2026, Q1 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn | 148.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 148.49 Mn |
| Mar 31, 2025 | 260.88 Mn |
| Dec 31, 2024 | 267.55 Mn |
| Sep 30, 2024 | 286.86 Mn |
| Jun 30, 2024 | 292.13 Mn |
| Mar 31, 2024 | 305.80 Mn |
| Mar 31, 2023 | 330.20 Mn |
| Jun 30, 2022 | 266.08 Mn |
| Jun 30, 2021 | 1.58 Bn |
| Jun 30, 2020 | 1.70 Bn |
| Jun 30, 2019 | 3.62 Bn |
| Jun 30, 2018 | 1.29 Bn |